Showing results (1161-1170 of 1,512) with videos related to
Sort By:
Pageof 152
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.Gastrointestinal Endoscopy|March 23, 2024
Impact of the suprapapillary method on patency in distal malignant biliary obstruction: a multicenter randomized controlled trialSung Woo Ko, Hyun Don Joo, Tae Jun Song, et al.Cancer Research and Treatment|July 22, 2015
VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic CarcinomaSeongyeol Park, Soo Jeong Nam, Bhumsuk Keam, et al.Journal of Clinical Medicine|April 3, 2021
Feasibility and Safety of Endoluminal Radiofrequency Ablation as a Rescue Treatment for Bilateral Metal Stent Obstruction Due to Tumor Ingrowth in the Hilum: A Pilot StudyHoonsub So, Chi Hyuk Oh, Tae Jun Song, et al.Translational Lung Cancer Research|March 15, 2021
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinomaMinsu Kang, Changhee Park, Se Hyun Kim, et al.Journal of Hypertension|October 10, 2022
Bidirectional association between SBP variability and arterial stiffness in patients with chronic kidney disease: findings from KNOW-CKD studyCheol Ho Park, Hyung Woo Kim, Jung Tak Park, et al.Nature Communications|September 6, 2022
Long read genome assemblies complemented by single cell RNA-sequencing reveal genetic and cellular mechanisms underlying the adaptive evolution of yakXue Gao, Sheng Wang, Yan-Fen Wang, et al.BMC Cancer|January 9, 2019
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitorsRyul Kim, Bhumsuk Keam, Sehui Kim, et al.JTO Clinical and Research Reports|October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLCYi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Pageof 152